Aziz  Mottiwala net worth and biography

Aziz Mottiwala Biography and Net Worth

Aziz has over 20 years of biopharmaceutical industry leadership experience in several therapeutic areas, including over 10 years in the eye care space. Prior to joining Tarsus, Aziz was Chief Commercial Officer at Opiant Pharmaceuticals, overseeing all aspects of commercial strategy for the company’s addiction medicine portfolio. Before that, he was Senior Vice President and Head of Commercial at Avanir Pharmaceuticals. He also spent over 10 years at Allergan (an AbbVie company), most recently as Vice President of Marketing for the company’s eye care franchise, where he helped grow the business to over $2 billion in revenue across a diverse portfolio including Restasis® and Lumigan®, as well as several other devices and OTC product lines.

Previously, Aziz held commercial leadership roles at Valeant, IMS Health (now IQVIA), and Aventis Pharmaceuticals (now Sanofi). He received a BS in biochemistry from the University of California San Diego and an MBA in marketing and finance from the Marshall School of Business at the University of Southern California. He is also heavily active in the community and serves on the boards of the Orange County nonprofit OneOC and Octane.

What is Aziz Mottiwala's net worth?

The estimated net worth of Aziz Mottiwala is at least $1.97 million as of March 18th, 2024. Mr. Mottiwala owns 54,075 shares of Tarsus Pharmaceuticals stock worth more than $1,965,626 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Mottiwala may own. Learn More about Aziz Mottiwala's net worth.

How do I contact Aziz Mottiwala?

The corporate mailing address for Mr. Mottiwala and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at [email protected]. Learn More on Aziz Mottiwala's contact information.

Has Aziz Mottiwala been buying or selling shares of Tarsus Pharmaceuticals?

During the last quarter, Aziz Mottiwala has sold $145,839.60 in shares of Tarsus Pharmaceuticals stock. Most recently, Aziz Mottiwala sold 4,766 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a transaction totalling $145,839.60. Following the completion of the sale, the insider now directly owns 54,075 shares of the company's stock, valued at $1,654,695. Learn More on Aziz Mottiwala's trading history.

Who are Tarsus Pharmaceuticals' active insiders?

Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), and Aziz Mottiwala (Insider). Learn More on Tarsus Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Tarsus Pharmaceuticals?

During the last year, Tarsus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 10,506 shares worth more than $178,660.80. During the last year, insiders at the sold shares 28 times. They sold a total of 297,136 shares worth more than $5,798,486.81. The most recent insider tranaction occured on March, 18th when insider Aziz Mottiwala sold 4,766 shares worth more than $145,839.60. Insiders at Tarsus Pharmaceuticals own 11.5% of the company. Learn More about insider trades at Tarsus Pharmaceuticals.

Information on this page was last updated on 3/18/2024.

Aziz Mottiwala Insider Trading History at Tarsus Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/18/2024Sell4,766$30.60$145,839.6054,075View SEC Filing Icon  
7/19/2023Sell2,400$20.05$48,120.0045,806View SEC Filing Icon  
6/8/2023Sell100$20.00$2,000.0048,086View SEC Filing Icon  
6/6/2023Sell2,143$18.61$39,881.2350,686View SEC Filing Icon  
11/15/2022Sell6,857$17.72$121,506.0449,729View SEC Filing Icon  
11/8/2021Sell1,889$28.11$53,099.79View SEC Filing Icon  
11/4/2021Sell100$28.03$2,803.00View SEC Filing Icon  
11/2/2021Sell6,000$26.78$160,680.00View SEC Filing Icon  
9/10/2021Sell2,593$22.15$57,434.9558,203View SEC Filing Icon  
See Full Table

Aziz Mottiwala Buying and Selling Activity at Tarsus Pharmaceuticals

This chart shows Aziz Mottiwala's buying and selling at Tarsus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $36.35
Low: $34.25
High: $37.16

50 Day Range

MA: $31.40
Low: $23.48
High: $39.22

2 Week Range

Now: $36.35
Low: $11.33
High: $40.40

Volume

1,033,264 shs

Average Volume

666,923 shs

Market Capitalization

$1.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07